{{distinguish|glipizide|glyburide}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 459476800
| IUPAC_name = ''N''-(hexahydrocyclopenta[''c'']pyrrol-2(1''H'')-ylcarbamoyl)-4-methylbenzenesulfonamide
| image = Gliclazide.svg
| image2 = Gliclazide-xtal-1999-ball-and-stick.png

<!--Clinical data-->
| tradename = Diamicron, others<ref>{{cite web|title=Gliclazide - Drugs.com|url=https://www.drugs.com/international/gliclazide.html|website=www.drugs.com|accessdate=27 December 2016}}</ref>
| Drugs.com = {{drugs.com|CONS|gliclazide}}
| pregnancy_AU = C
| legal_AU = S4
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life = 10.4 hours
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 21187-98-4
| ATC_prefix = A10
| ATC_suffix = BB09
| PubChem = 3475
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01120
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3356
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = G4PX8C4HKV
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01599
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 31654
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 427216
<!--Chemical data-->
| C=15 | H=21 | N=3 | O=3 | S=1
| molecular_weight = 323.412 g/mol
| SMILES = O=S(=O)(c1ccc(cc1)C)NC(=O)NN3CC2CCCC2C3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BOVGTQGAOIONJV-UHFFFAOYSA-N
}}
<!-- Definition and medical uses -->
'''Gliclazide''', sold under the brand name '''Diamicron''' among others, is an [[anti-diabetic medication]] used to treat [[diabetes mellitus type 2]].<ref name=BNF69/> It is used when dietary changes, exercise, and weight loss are not enough.<ref name=UK2016>{{cite web|title=Bilxona 30mg Modified-release Tablets - Summary of Product Characteristics (SPC) - (eMC)|url=http://www.medicines.org.uk/emc/medicine/31089|website=www.medicines.org.uk|accessdate=27 December 2016|date=29 August 2016}}</ref> It is taken by mouth.<ref name=BNF69>{{cite book|title=British national formulary : BNF 69|date=2015|publisher=British Medical Association|isbn=9780857111562|page=474|edition=69}}</ref>

<!-- Side effects and mechanism -->
Side effect may include [[low blood sugar]], vomiting, [[abdominal pain]], rash, and [[liver problems]].<ref name=UK2016/><ref name=BNF69/> Use by those with significant [[kidney problems]], liver problems, or who are [[pregnancy|pregnant]] is not recommended.<ref name=BNF69/><ref name=UK2016/> Gliclazide is in the [[sulfonylurea]] family of medications.<ref name=BNF69/> It works mostly by increasing the release of [[insulin]].<ref name=BNF69/>

<!-- History and culture -->
Gliclazide was patented in 1966 and approved for medical use in 1972.<ref name=Fis2006>{{cite book|last1=Fischer|first1=Janos|last2=Ganellin|first2=C. Robin|title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=449|url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA449|language=en}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015}}</ref> The wholesale cost in the [[developing world]] is about 2.46 to 3.92 USD per month.<ref name=ERC2014>{{cite web|title=Gliclazide|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=GLIC80T&s_year=2014&year=2014&str=80%20mg&desc=Gliclazide&pack=new&frm=TAB-CAP&rte=PO&class_code2=18%2E5%2E&supplement=&class_name=%2818%2E5%2E%29Insulins%20and%20medicines%20used%20for%20diabetes%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref> In the United Kingdom a month of medication costs the [[NHS]] about 2.12 pounds.<ref name=BNF69/> It is not available for sale in the United States.<ref>{{cite web|title=Gliclazide Advanced Patient Information - Drugs.com|url=https://www.drugs.com/cons/gliclazide.html|website=www.drugs.com|accessdate=27 December 2016}}</ref>

== Medical uses ==
Gliclazide is used for control of hyperglycemia in gliclazide-responsive [[diabetes mellitus]] of stable, mild, non-[[ketosis]] prone, type 2 diabetes. It is used when diabetes cannot be controlled by proper dietary management and exercise or when insulin therapy is not appropriate.{{Citation needed|date=September 2011}}
National Kidney Foundation (2012 Update) claims that Gliclazide does not require dosage uptitration even in end stage kidney disease.

== Contraindications ==
*Type 1 diabetes{{Citation needed|date=September 2011}}
*Hypersensitivity to [[sulfonylureas]]{{Citation needed|date=September 2011}}
*Severe renal or hepatic failure{{Citation needed|date=September 2011}} (But relatively useful in mild renal impairment e.g. CKD stage 3)
*Pregnancy and lactation{{Citation needed|date=September 2011}}

== Adverse effects ==
*[[Hypoglycemia]] - while it was shown to have the same efficacy as glimepiride, one of the newer sulfonylureas, the European GUIDE study has shown that it has approximately 50% less hypoglycaemic confirmed episodes in comparison with glimepiride.<ref>{{cite journal |doi=10.1111/j.1365-2362.2004.01381.x |title=GUIDE study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients |year=2004 |last1=Schernthaner |first1=G. |last2=Grimaldi |first2=A. |last3=Di Mario |first3=U. |last4=Drzewoski |first4=J. |last5=Kempler |first5=P. |last6=Kvapil |first6=M. |last7=Novials |first7=A. |last8=Rottiers |first8=R. |last9=Rutten |first9=G. E. H. M. |last10=Shaw |first10=K. M. |journal=European Journal of Clinical Investigation |volume=34 |issue=8 |pages=535–42 |pmid=15305887|display-authors=8 }}</ref>
*Gastrointestinal disturbance (reported){{Citation needed|date=September 2011}}
*Skin reactions (rare){{Citation needed|date=September 2011}}
*Hematological disorders (rare){{Citation needed|date=September 2011}}
*Hepatic enzyme rises (exceptional){{Citation needed|date=September 2011}}

== Interactions ==
Hyperglycemic action may be caused by [[danazol]], [[chlorpromazine]], [[glucocorticoids]], [[progestogens]], or β-2 agonists. Its hypoglycemic action may be potentiated by [[phenylbutazone]], alcohol, [[fluconazole]], β-blockers, and possibly [[ACE inhibitors]]. It has been found that rifampin increases gliclazide metabolism in humans in vivo.<ref>{{cite journal |doi=10.1016/S0009-9236(03)00221-2 |title=Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide |year=2003 |last1=Park |first1=J |journal=Clinical Pharmacology & Therapeutics |volume=74 |issue=4 |pmid=14534520 |pages=334–40 |last2=Kim |first2=KA |last3=Park |first3=PW |last4=Park |first4=CW |last5=Shin |first5=JG}}</ref>

== Overdose ==
Gliclazide overdose may cause severe hypoglycemia, requiring urgent administration of glucose by IV and monitoring.{{Citation needed|date=September 2011}}

== Mechanism of action ==
Gliclazide selectively binds to sulfonylurea receptors (SUR-1) on the surface of the pancreatic beta-cells. It was shown to provide cardiovascular protection as it does not bind to sulfonylurea receptors (SUR-2A) in the heart.<ref>{{cite journal |pages=1019–25 |doi=10.1007/s001250100595 |title=Gliclazide produces high-affinity block of K ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells |year=2001 |last1=Lawrence |first1=C. L. |last2=Proks |first2=P. |last3=Rodrigo |first3=G. C. |last4=Jones |first4=P. |last5=Hayabuchi |first5=Y. |last6=Standen |first6=N. B. |last7=Ashcroft |first7=F. M. |journal=Diabetologia |volume=44 |issue=8 |pmid=11484080}}</ref> This binding effectively closes the K+ ion channels. This decreases the efflux of potassium from the cell which leads to the depolarization of the cell. This causes voltage dependent Ca++ ion channels to open increasing the Ca++ influx. The calcium can then bind to and activate calmodulin which in turn leads to exocytosis of insulin vesicles leading to insulin release.{{Citation needed|date=September 2011}} The mouse model of MODY diabetes suggested that the reduced gliclazide clearance stands behind their therapeutic success in human MODY patients, but Urbanova et al. found that human MODY patients respond differently and that there was no consistent decrease in gliclazide clearance in randomly selected HNF1A-MODY and HNF4A-MODY patients.<ref name="Urbanova et al. 2015"/>

Its classification has been ambiguous, as literature uses it as both a first-generation <ref name="pmid2106423">{{cite journal |pages=109–14 |doi=10.1016/0168-8227(90)90020-T |title=Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds |year=1990 |last1=Ballagi-Pordány |first1=György |last2=Köszeghy |first2=Anna |last3=Koltai |first3=Mária-Zsófia |last4=Aranyi |first4=Zoltán |last5=Pogátsa |first5=Gábor |journal=Diabetes Research and Clinical Practice |volume=8 |issue=2 |pmid=2106423}}</ref> and second-generation<ref>{{cite journal |pages=722–30 |doi=10.1016/j.metabol.2006.01.019 |title=Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation |year=2006 |last1=Shimoyama |first1=Tatsuhiro |last2=Yamaguchi |first2=Shinya |last3=Takahashi |first3=Kazuto |last4=Katsuta |first4=Hidenori |last5=Ito |first5=Eisuke |last6=Seki |first6=Hiroyuki |last7=Ushikawa |first7=Kenji |last8=Katahira |first8=Hiroshi |last9=Yoshimoto |first9=Katsuhiko |last10=Ohno |first10=Hideki |last11=Nagamatsu |first11=Shinya |last12=Ishida |first12=Hitoshi |journal=Metabolism |volume=55 |issue=6 |pmid=16713429|display-authors=8 }}</ref> sulfonylurea.

== Properties ==
Water solubility = 0.027&nbsp;mg/L<ref>Gopal Venkatesh Shavi et al. Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques; International Journal of Drug Delivery 2 (2010) 49-57</ref>
*Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity.{{Citation needed|date=September 2011}}
*Glycemia-independent hemovascular effects, antioxidant effect.{{Citation needed|date=September 2011}}
*No active circulating metabolites.{{Citation needed|date=September 2011}}

== Metabolism ==
Gliclazide undergoes extensive metabolism to several inactive metabolites in human beings, mainly methylhydroxygliclazide and carboxygliclazide. CYP2C9 is involved in the formation of hydroxygliclazide in human liver microsomes and in a panel of recombinant human P450s in vitro.<ref>{{cite journal |pmid=8719909 |year=1995 |last1=Rieutord |first1=A |last2=Stupans |first2=I |last3=Shenfield |first3=GM |last4=Gross |first4=AS |title=Gliclazide hydroxylation by rat liver microsomes |volume=25 |issue=12 |pages=1345–54 |journal=Xenobiotica |doi=10.3109/00498259509061922}}</ref><ref>{{cite journal |pages=450–7 |doi=10.1111/j.1365-2125.2007.02943.x |pmc=2048545 |title=Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination |year=2007 |last1=Elliot |first1=David J. |last2=Lewis |first2=Benjamin C. |last3=Gillam |first3=Elizabeth M. J. |last4=Birkett |first4=Donald J. |last5=Gross |first5=Annette S. |last6=Miners |first6=John O. |journal=British Journal of Clinical Pharmacology |volume=64 |issue=4 |pmid=17517049 |last7=Miners |first7=JO}}</ref> But the pharmacokinetics of gliclazide MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP2C9 genetic polymorphism.<ref>{{cite journal |doi=10.1111/j.1365-2125.2007.02846.x |title=Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects |year=2007 |last1=Zhang |first1=Yifan |last2=Si |first2=Dayong |last3=Chen |first3=Xiaoyan |last4=Lin |first4=Nan |last5=Guo |first5=Yingjie |last6=Zhou |first6=Hui |last7=Zhong |first7=Dafang |journal=British Journal of Clinical Pharmacology |volume=64 |pages=67–74 |pmid=17298483 |issue=1 |pmc=2000619}}</ref><ref>{{cite journal |pages=1579–86 |doi=10.1038/sj.bjp.0707685 |title=Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide |year=2009 |last1=Xu |first1=H |last2=Williams |first2=K M |last3=Liauw |first3=W S |last4=Murray |first4=M |last5=Day |first5=R O |last6=McLachlan |first6=A J |journal=[[British Journal of Pharmacology]] |volume=153 |issue=7 |pmid=18204476 |pmc=2437900}}</ref>

==References==
{{reflist|32em|refs=
<ref name="Urbanova et al. 2015">{{Cite journal |last1=Urbanova |first1=J. |year=2015 |title=Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a-/- Model |journal=Current Pharmaceutical Design |volume=21 |pages=5736–5748 |doi=10.2174/1381612821666151008124036|display-authors=etal}}</ref>}}

==External links==
*[http://www.servier.com SERVIER]
*[http://www.advance-trial.com Advance] clinical trial on diabetes

{{Oral hypoglycemics}}
{{Ion channel modulators}}

[[Category:Potassium channel blockers]]
[[Category:Sulfonylureas]]
[[Category:Laboratoires Servier]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]
[[Category:Cyclopentanes]]